WVE Stock Drops 30% on INLIGHT Obesity Trial Data WVE stock plunged 30% after Wave Life Sciences released Phase 1 INLIGHT trial results. See what the data showed and why investors sold off shares.

WVE Stock Drops 30% on INLIGHT Obesity Trial Data
WVE stock plunged 30% after Wave Life Sciences released Phase 1 INLIGHT trial results. See what the data showed and why investors sold off sh...

#WVE #WaveLifeSciences #INLIGHT #ObesityTrial #BiotechStocks
https://scrollworthy.org/trending/wve-stock

2 Biotech Giants to Buy in 2026

"Biotech Boom Ahead! $MRNA, $BMRN lead the charge in 2026 with innovative treatments for tough diseases. Growth potential abounds!
#BiotechStocks #GrowthInvesting #HealthcareInnovation"

https://a777.lt/SnruEK

Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing This clinical-stage biotech develops precision oncology therapies and diagnostics targeting unmet needs in breast and ovarian cancer.

$CELC Soars as Investment Manager Boosts Stake by 135,000 Shares!
Clinical-stage biotech firm targets breast & ovarian cancer with precision therapies & diagnostics
#BiotechStocks #CancerTreatment #StockMarketNews

https://a777.lt/LzhTfp

$NVO's obesity drug fails to impress, loses billions in market value to $LLY rival
#obesitydrug #NVO #LLY #biotechstocks

https://a777.lt/pKiTWp

Big Surge: $ACLX stock up 80% as Gilead Sciences buys it for $7.8B in all-cash deal
$ACLX surges on Gilead's $7.8B acquisition
#stockmarket #acquisition #biotechstocks

https://a777.lt/6f5ymv

$PGEN Soars on FDA Approval of PAPZIMEOS for RRP Treatment!
Precigen surges after historic approval of its first-in-class RRP therapy
#PGEN #BiotechStocks #FDAApproved

https://a777.lt/73YoM7

Nektar's stock rises 51% on Phase II Rezpeg AD maintenance win

Nektar's $NKTR surges 51% on Rezpeg AD success!
Nektar Therapeutics stock rallies after rezpegaldesleukin shows promise in Phase II AD trial with flexible dosing regimens.

#NektarTherapeutics #BiotechStocks #StockMarketNews

https://a777.lt/8SF9o5

$QNCX Stock Surges 300% on Buyout Rumors!
Quince Therapeutics ($QNCX) soars after hiring LifeSci Capital to explore sale or partnerships.
#StockMarket #Buyout #BiotechStocks

https://a777.lt/tyjj9w

$ALNY Earnings Alert: Can TTR Drug Save the Day?
Alnylam Pharmaceuticals reports Q4 2025 results Thursday, investors await TTR drug update
#ALNY #BiotechStocks #EarningsSeason

https://a777.lt/re2pTG

#SNGX Published Phase 2a results for SGX945 add clinical validation to Soligenix's Behçet’s disease program.

#BiotechStocks #SmallCaps #ClinicalTrials

youtu.be/hnrktxdh52g

#TOVX #TherivaBiologics #StockMarket #BiotechStocks #TechnicalAnalysis #Investing #AMEX #SmallCap #StockAnalysis #RSI #MACD #StockForecasting #HealthStocks #BiologicalTreatments #DayTrading #FinanceNews #HoldRating #MarketIndicators #StockUpdate #InvestmentStrategy youtu.be/wbPdAXT_ofw

FDA approval, Breakthrough Therapy status and an early Alzheimer’s trial reshape Arrowhead Pharmaceuticals’ outlook.

longevity.technology/news/arrowhe...

#longevity #biotech #RNAi #PharmaInnovation #HealthcareInvesting #BiotechStocks #DrugDiscovery #PrecisionMedicine #FDAApproval

#NNVC NanoViricides is preparing for a Phase 2 trial of NV-387 for Mpox, expected to begin in late 2025 or early 2026. Results could set the stage for stockpile programs and broader antiviral use. #NanoViricides #BiotechStocks #Antivirals

youtu.be/7bJAJ82Dltc

💹 Chart of the Day: Viking Therapeutics (VKTX) - FFR Trading Viking Therapeutics (VKTX) gains momentum on strong trial progress and buyout rumors. See why traders are watching closely.

💹 Chart of the Day: $VKTX

Biotech is heating up again 🔥
Viking Therapeutics is gaining momentum with strong Phase 3 progress — and even buyout rumors from Pfizer. 👀

Could $VKTX be the next big breakout?
📈 Read more: zurl.co/ukSTd

#VKTX #BiotechStocks #Trading

Dr. Ann Childress, principal investigator on Cingulate's CTx-1301 trials, shares a story about ADHD medications that only work for part of the day.
$CING
#Cingulate #ADHD #Neuroscience #Biotech #BiotechStocks #LifeSciences #NASDAQ

From Injections to Pills: Why Crinetics (CRNX) Could Be Biotech’s Next Breakout Paltusotine Positions Crinetics as a Potential Endocrine Market Disruptor Amid Biotech’s Risk-On Recovery

$CRNX is aiming to disrupt a $1.6B market with oral Paltusotine. First oral alternative in acromegaly could reshape endocrinology. Full Signal Pathway deep dive signalpathway.substack.com/p/from-injec... #Biotech #CRNX #BiotechStocks

Explore Dyadic’s Revenue Opportunities in DNase1 with Unboxing Biotech & $DYAI COO Joe Hazelton.
#Biotechnology #LifeSciences #SyntheticBiology #ProteinEngineering #IndustrialBiotech #Biomanufacturing #EnzymeTechnology #DrugDevelopment #TherapeuticProteins #Biopharma #BiotechNews #BiotechStocks

A Biotech Stock With First-Mover Edge

#BiotechStocks #FDAApproval #LungHealth

Chart of the Day: Halozyme Therapeutics (HALO) Eyes Gap Refill - FFR Trading Halozyme Therapeutics (HALO) targets a gap refill to $64 after strong earnings, analyst upgrades, and legislative tailwinds.

💊 Chart of the Day: Halozyme Therapeutics (HALO)

HALO is showing bullish momentum after strong earnings and legislative tailwinds. A gap refill to $64 could be next. 📈

Read more 👉 zurl.co/WlfNI
#HALO #StockMarket #BiotechStocks

🚀 Exciting times for #TNYA! Successful Phase 2 trial results could spark volatility. Watch for a breakout above $0.68, targeting $0.72 & $0.75. RSI near oversold & MACD bearish, so stay cautious. Biotech buzz is real, but keep an eye on regulatory news! #FeetrAI #BiotechStocks

Tenaya Therapeutics stock rises after positive safety reviews for heart gene therapies Investing.com -- Tenaya Therapeutics Inc (NASDAQ:TNYA) stock climbed 4.2% following positive safety endorsements from independent monitoring boards for its two cardiovascular gene therapy clinical trials. The clinical-stage biotechnology company announced that Data Safety and Monitoring Boards (DSMBs) have approved the continuation of both the MyPEAK-1 trial for TN-201 and the RIDGE-1 trial for TN-401 according to protocol. The endorsements allow Tenaya to proceed with expansion cohorts for TN-201 and to both expand at the current dose and escalate to a higher dose level for TN-401. "Safety is paramount, and this milestone reinforces the favorable tolerability profile emerging for both TN-201 and TN-401 and highlights the appropriateness of our immunosuppressant regimen to manage patients," said Whit Tingley, Tenaya’s Chief Medical Officer. For the MyPEAK-1 Phase 1b/2 trial, which targets MYBPC3-associated hypertrophic cardiomyopathy, the DSMB review followed enrollment of the first three patients at the 6E13 vg/kg dose (Cohort 2). The board determined that TN-201 has an acceptable safety profile to allow enrollment of expansion cohorts at either the 3E13 vg/kg or 6E13 vg/kg dose levels. Initial data from the first three patients in Cohort 1 showed that TN-201 reached cardiomyocytes with robust RNA expression. Increased MyBP-C protein levels were observed in two patients with serial biopsies available. All three patients achieved New York Heart Association Class I post-treatment, indicating resolution of heart failure symptoms. For the RIDGE-1 trial, which targets PKP2-associated arrhythmogenic right ventricular cardiomyopathy, the DSMB endorsed dose escalation to the 6E13 vg/kg level after reviewing data from the first three patients at the 3E13 vg/kg dose. Tenaya plans to report longer-term follow-up data from the MyPEAK-1 trial’s Cohort 1 and initial data from Cohort 2 in the fourth quarter of this year. Initial data from the RIDGE-1 trial’s Cohort 1 is expected in the fourth quarter of 2025. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Sure, there are always opportunities in the stock market – but finding them feels more difficult now than a year ago. Unsure where to invest next? One of the best ways to discover new high-potential opportunities is to look at the top performing portfolios this year. ProPicks AI offers 6 model portfolios from Investing.com which identify the best stocks for investors to buy right now. For example, ProPicks AI found 9 overlooked stocks that jumped over 25% this year alone. The new stocks that made the monthly cut could yield enormous returns in the coming years. Is TNYA one of them?

Click Subscribe #TenayaTherapeutics #GeneTherapy #HeartHealth #BiotechStocks #StockMarket

Novo Nordisk Stock 2025: Should You Buy Now? Novo Nordisk stock drops 3.77% to .00, with pre-market panic pushing it down 19%. Is this a short-term dip or a long-term opportunity?

🔹 Novo Nordisk Stock Takes a Hit

📉 Novo Nordisk stock closed at $69 with a massive 19% pre-market plunge!

💊 Dive into what caused the drop and what experts say.
🔗 allnewtrending.com/novo-nordisk...

#news #USA
#NovoNordisk #NVO #BiotechStocks #StockMarketNews #InvestSmart

When Will Gene Editing Stocks Finally Take Off? - Nanalyze When Will Gene Editing Stocks Finally Take Off?  Nanalyze

Click Subscribe #GeneEditing #BiotechStocks #Investing #StockMarket #Innovation

Sonnet BioTherapeutics stock soars after $888 million crypto deal Investing.com -- Sonnet BioTherapeutics (NASDAQ:SONN) stock skyrocketed 290% following the announcement of an $888 million business combination that will transform the company into a cryptocurrency treasury focused on HYPE tokens. The biopharmaceutical company has entered into a definitive agreement with Rorschach I LLC, a newly-formed entity backed by Atlas Merchant Capital and Paradigm Operations LP, to create Hyperliquid Strategies Inc. The new entity is expected to hold approximately 12.6 million HYPE tokens, valued at $583 million, plus gross cash of at least $305 million at closing. The transaction includes participation from prominent crypto investors including Paradigm, Galaxy Digital (TSX:GLXY), Pantera Capital, D1 Capital, Republic Digital, and 683 Capital. Upon completion, the company will remain listed on Nasdaq under a new ticker symbol. Bob Diamond, Co-founder and CEO of Atlas, will become Chairman of the Board while David Schamis, CIO and Co-founder of Atlas, will serve as Chief Executive Officer of the new entity. The company plans to add new board members, including Eric Rosengren, former President of the Boston Fed. "We are delighted by this opportunity to partner with Sonnet in establishing a leading crypto treasury management strategy to ultimately deliver strong value to shareholders," said Diamond. "We believe HYPE and the Hyperliquid protocol represent a truly differentiated offering within the digital asset space." As part of the agreement, Sonnet will raise $5.5 million through a private placement to accredited investors, expected to close on July 14, 2025. Additionally, $2 million in convertible notes sold in June 2025 will convert into shares of convertible preferred stock and warrants. Following the business combination, Sonnet will operate as a wholly owned subsidiary of Hyperliquid Strategies, continuing to develop its biotech assets including SON-1010. Current Sonnet shareholders will receive a CVR related to the biotech assets. The transaction is expected to close in the second half of this year, subject to Sonnet stockholder approval and other customary conditions. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #SonnetBioTherapeutics #StockMarket #CryptoDeal #InvestmentNews #BiotechStocks

Viking Therapeutics (VKTX) Could Be Ready to Run Again - FFR Trading VKTX is gaining attention as its obesity drug trials progress. Here's why Viking Therapeutics VKTX could be poised for another breakout.

🚨 Chart of the Day: Viking Therapeutics (VKTX)
VKTX could be gearing up for another breakout 📈

Get the full breakdown here 👇
🔗 zurl.co/DCAI7

#VKTX #BiotechStocks #ObesityDrugs #StockMarket

Click Subscribe #AIBiotech #InvestmentNews #MarketTrends #BiotechStocks #AIResearch

How Is Incyte’s Stock Performance Compared to Other Biotech Stocks? - Yahoo Finance How Is Incyte’s Stock Performance Compared to Other Biotech Stocks?  Yahoo Finance

Click Subscribe #Investing #BiotechStocks #StockMarket #FinanceNews #Incyte

TuHURA Biosciences stock rises following FDA hold lift Investing.com -- TuHURA Biosciences Inc (NASDAQ:HURA) shares climbed 5% today after the U.S. Food and Drug Administration (FDA) lifted a manufacturing-related partial clinical hold on the company’s Phase 3 trial for its cancer treatment, IFx-2.0. This move allows the trial to proceed under the Special Protocol Assessment (SPA) Agreement previously established with the FDA. The clinical hold’s removal has been positively received by the market as it signals a step forward for TuHURA’s IFx-2.0, which is being developed as an adjunctive therapy in combination with Keytruda® for the treatment of advanced or metastatic Merkel Cell Carcinoma (MCC). The trial is set to enroll 118 patients across 22 to 25 U.S. sites. James Bianco, M.D., President and CEO of TuHURA Biosciences, expressed gratitude for the FDA’s quick response and useful recommendations, which have led to the resumption of the trial. Dr. Bianco also highlighted the financial benefit of the hold’s removal, triggering an additional $2.23 million payment to the company under a recent private placement agreement. The pivotal trial aims to demonstrate the efficacy of IFx-2.0 in improving Overall Response Rate (ORR) and Progression Free Survival (PFS) when used with Keytruda®, compared to Keytruda® plus placebo. Successful achievement of the ORR primary endpoint could lead to accelerated approval, and a positive PFS result may satisfy the requirements for regular approval, potentially without the need for a post-approval confirmatory trial. Investors appear to be optimistic about TuHURA’s progress, as reflected in the stock’s performance today. The company’s ability to move forward with its Phase 3 trial is a significant milestone in the development of IFx-2.0 and could have important implications for patients with MCC. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #TuHURABiosciences #StockMarket #FDALift #BiotechStocks #Investing

Cidara Therapeutics ($CDTX) is gearing up for Phase 2b results of its flu antiviral, CD388, this month. Analysts are bullish, with price targets up to $50. Stock up 4.6% post-earnings.

Read more: www.valuethemarkets.com/analysis/cid...

#CDTX #BiotechStocks #AntiviralResearch #ValueTheMarkets

Guardant Health shares rise following FDA breakthrough designation GH hereremove ads Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #GuardantHealth #FDABreakthrough #StockMarket #HealthcareInnovation #BiotechStocks